Search for drugs:
Typing the drug name to query
ZIV-AFLIBERCEPT
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Cardiac Electrophysiology
- The effect of 6 mg per kg intravenous ZALTRAP every three weeks on QTc interval was evaluated in 87 patients with solid tumors in a randomized, placebo-controlled study. No large changes in the mean QT interval from baseline (i.e., greater than 20 ms as corrected for placebo) based on Fridericia correction method were detected in the study. However, a small increase in the mean QTc interval (i.e., less than 10 ms) cannot be excluded due to limitations of the study design.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
0
24092
Other ADRs
0
38381587
Odds Ratio = N/A
Drug Property Information
ATC Code(s):
- L01XX44 - ziv-aflibercept
- L01XX4 -
- L01XX - Other antineoplastic agents
- L01X - OTHER ANTINEOPLASTIC AGENTS
- L01 - ANTINEOPLASTIC AGENTS
- L - ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
- S01LA05 - ziv-aflibercept
- S01LA - Antineovascularisation agents
- S01L - OCULAR VASCULAR DISORDER AGENTS
- S01 - OPHTHALMOLOGICALS
- S - SENSORY ORGANS
Active Ingredient:AFLIBERCEPT
Active Ingredient UNII:15C2VL427D
Drugbank ID:DB08885
PubChem Compound:N/ADIR Classification
CAS Number:
Dosage Form(s):solution, concentrate
Route(s) Of Administrator:intravenous
Daily Dose:
Chemical Structure: 
SMILE Code:
Reference
N/A
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.